Trobalt

This page shows the latest Trobalt news and features for those working in and with pharma, biotech and healthcare.

GSK/ Valeant's Trobalt set for EU restrictions

European regulatory advisors have recommended GlaxoSmithKline and Valeant's epilepsy drug Trobalt be restricted after safety concerns over its use emerged. ... The CHMP said the move followed cases of abnormal colouring of the skin, nails, lips and eye

Latest news

Therapy focus: Epilepsy

In May 2011, GlaxoSmithKline launched its new epilepsy medicine Trobalt in the UK.
FDA approves GSK/Valeant anti-seizure drug

In the EU, ezogabine is known as retigabine (Trobalt). The drug received marketing authorisation in the EU in March 2011.
GSK launches first-in-class epilepsy drug

GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures. ... GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with
GSK sales fall for first quarter of 2011

Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Country report: The healthcare market in Germany

Committee and the same 'no proof' decision was reached regarding GlaxoSmithKline's Trobalt (retigabine) for epilepsy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Medical Writer/ Senior Medical Writer opportunities – Macclesfie...: competitive salary and benefits package

Subscribe to our email news alerts

PMHub

Add my company

BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

My MS journey: one patient's search for innovation: David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.: Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?: Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...